Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
46.8M
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
7.08M
-
Shares change
-
+2.54M
-
Total reported value, excl. options
-
$8.64M
-
Value change
-
+$2.8M
-
Put/Call ratio
-
0.45
-
Number of buys
-
36
-
Number of sells
-
-23
-
Price
-
$1.22
Significant Holders of Outlook Therapeutics, Inc. - Common Stock, $0.01 par value per share (OTLK) as of Q1 2025
76 filings reported holding OTLK - Outlook Therapeutics, Inc. - Common Stock, $0.01 par value per share as of Q1 2025.
Outlook Therapeutics, Inc. - Common Stock, $0.01 par value per share (OTLK) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.08M shares
of 46.8M outstanding shares and own 15.15% of the company stock.
Largest 10 shareholders include Schonfeld Strategic Advisors LLC (1.55M shares), BlackRock, Inc. (1.24M shares), SPHERA FUNDS MANAGEMENT LTD. (857K shares), VANGUARD GROUP INC (837K shares), GEODE CAPITAL MANAGEMENT, LLC (434K shares), TANG CAPITAL MANAGEMENT LLC (400K shares), Steward Partners Investment Advisory, LLC (366K shares), STATE STREET CORP (288K shares), FMR LLC (175K shares), and NORTHERN TRUST CORP (127K shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.